Cargando…

Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide

BACKGROUND: We previously identified three short single peptides (P4, P6 and P7) representing different B-cell epitopes on the extracellular domain of Her-2/neu for a vaccine that was tested in a phase-I clinical trial. Here we describe the improvement of the multi peptide vaccine by fusing the sing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tobias, Joshua, Jasinska, Joanna, Baier, Karin, Kundi, Michael, Ede, Nicholas, Zielinski, Christoph, Wiedermann, Ursula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301331/ https://www.ncbi.nlm.nih.gov/pubmed/28183282 http://dx.doi.org/10.1186/s12885-017-3098-7

Ejemplares similares

Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model
por: Tobias, Joshua, et al.
Publicado: (2022)

Monomeric crystal structure of the vaccine carrier protein CRM(197) and implications for vaccine development
por: Gallagher, D. Travis, et al.
Publicado: (2023)

Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer
por: Tobias, Joshua, et al.
Publicado: (2022)

Site‐Specific Multi‐Functionalization of the Carrier Protein CRM(197) by Disulfide Rebridging for Conjugate Vaccine Development
por: Trattnig, Nino, et al.
Publicado: (2022)

Investigating the Deoxyribonuclease Activity of CRM197 with Site-Directed Mutagenesis
por: Bravo-Bautista, Nathalie, et al.
Publicado: (2019)

Structural and immunological characterization of E. coli derived recombinant CRM(197) protein used as carrier in conjugate vaccines
por: Mishra, Ravi P.N., et al.
Publicado: (2018)

Post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China
por: Hu, Ran, et al.
Publicado: (2023)

Conjugation with 8-arm PEG and CRM(197) enhances the immunogenicity of SARS-CoV-2 ORF8 protein
por: Tang, Xiaozhao, et al.
Publicado: (2022)

Click chemistry compared to thiol chemistry for the synthesis of site-selective glycoconjugate vaccines using CRM(197) as carrier protein
por: Stefanetti, G., et al.
Publicado: (2020)

O:2-CRM(197) Conjugates against Salmonella Paratyphi A
por: Micoli, Francesca, et al.
Publicado: (2012)

Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer
por: Goulielmaki, Maria, et al.
Publicado: (2023)

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022)

Efficient recovery of recombinant CRM197 expressed as inclusion bodies in E.coli
por: Park, Ah-Reum, et al.
Publicado: (2018)

Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022)

Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma
por: Höbel, Sabrina, et al.
Publicado: (2011)

Intracellular trafficking of diphtheria toxin and its mutated form, CRM197, in the endocytic pathway
por: Edis, Bilge Ozerman, et al.
Publicado: (2018)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

Safety, Immunogenicity and Dose Ranging of a New Vi-CRM(197) Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy Adults
por: van Damme, Pierre, et al.
Publicado: (2011)

Production in Escherichia coli of recombinant COVID-19 spike protein fragments fused to CRM197
por: Bellone, Maria Laura, et al.
Publicado: (2021)

Lack of seroprotection against diphtheria in the Austrian population, in light of reported diphtheria cases in Europe, 2022
por: Wagner, Angelika, et al.
Publicado: (2023)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Comparison of Immune Responses to Two Quadrivalent Meningococcal Conjugate Vaccines (CRM197 and Diphtheria Toxoid) in Healthy Adults
por: Kim, Han Wool, et al.
Publicado: (2019)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity
por: Graham, Barney S., et al.
Publicado: (2010)

Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
por: Ascarateil, Stephane, et al.
Publicado: (2015)

Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM(197) conjugate vaccine
por: Micoli, Francesca, et al.
Publicado: (2020)

Sustained release of actives with Montanide™ ISA 51 VG and Montanide™ ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
por: Ascarateil, Stephane, et al.
Publicado: (2015)

CRM197 reverses paclitaxel resistance by inhibiting the NAC‐1/Gadd45 pathway in paclitaxel‐resistant ovarian cancer cells
por: Tang, Xiao‐han, et al.
Publicado: (2019)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules
por: Wagner, Angelika, et al.
Publicado: (2018)

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02
por: Roestenberg, Meta, et al.
Publicado: (2008)

Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments
por: Wagner, Angelika, et al.
Publicado: (2021)

Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM
por: Kim, Han Wool, et al.
Publicado: (2016)

Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8(+) T Cells Specific for HER2/neu Epitopes
por: Kuznetsova, Maria, et al.
Publicado: (2019)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques
por: Kusi, Kwadwo A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_dk95bo8o7sdst4an3plno1n43l